



UNIVERSITÀ
CATTOLICA
del Sacro Cuore

CONVEGNO MICROANGIOPATIE TROMBOTICHE UCSC 2016

Roma, 19 febbraio 2016

Fondazione Policlinico Universitario A. Gemelli

Largo Agostino Gemelli, 8 - 00168 Roma (Aula Brasca)

Approccio morfologico alle microangiopatie trombotiche

Gina Zini

Polo Oncologia e Ematologia

Policlinico A. Gemelli

Università Cattolica S. Cuore - Roma

Thrombotic microangiopathies

Occlusive microangiopathic disorders with

- Microvascular thrombosis
- Thrombocytopenia
- Red blood cell mechanical damage

History (I)

Moschcowitz (1924)

First description of a 16 year-old girl who died within 2 weeks after the abrupt onset and progression of petechial bleeding, pallor, fever, paralysis, hematuria and coma. Disseminated microvascular hyaline thrombi largely composed of platelets were detected at autopsy in arterioles and capillaries.

In January of 1924¹ and apparently for a second time in February,² Moschcowitz presented a case before the New York Pathological Society of “a hitherto undescribed disease (ref. 1 at 21)” that he felt was “remarkable, clinically and anatomically (ref. 2 at 89).” A healthy 16-year-old girl suddenly developed weakness in her arms, pain on moving her wrists and elbows, pallor, and fever (38°C-39°C). Her symptoms worsened and on the tenth day of illness she was admitted to the hospital with anemia, leukocytosis, a few petechiae on one arm, and occult blood in gastric contents and stool. The serum creatinine was normal. Four days later she developed mild left hemiparesis and facial paralysis. The next day she became comatose and died. A limited autopsy showed hyaline thrombi in terminal arterioles and capillaries of the heart, kidney, spleen, and liver; the lungs were spared. Moschcowitz did not obtain a platelet count and did not report schistocytes in the blood film, so we do not have a complete description from him of thrombocytopenia or microangiopathic hemolytic anemia. But based on the pathology at autopsy, we recognize this patient as the first published example of idiopathic thrombotic thrombocytopenic purpura (TTP).

History (II)

Singer (1947):

First introduction of the term Thrombotic Thrombocytopenic Purpura (TTP).

Symmers (1952):

First introduction of the term Thrombotic Micro-Angiopathy (TMA) to describe the vascular lesions observed in TTP.

Gasser (1955):

First introduction of the term Hemolytic Uremic Syndrome (HUS) in a child presenting with hemolytic anemia, thrombocytopenia and renal failure with diffuse bilateral cortical necrosis.

Moake (1982):

First pathogenetic hypothesis: patients with relapsed chronic TTP show plasmatic large amount of “vWF unusual large multimers” delivered by endothelial cells.



Karmali (1985):

First association between HUS and *Escherichia Coli* Shiga toxin.

Clinical & pathological manifestations



Microangiopathy	Pathogenesis	Clinical presentation
Systemic platelet thrombi	Reduced capability to cleave vWF large multimers	Thrombotic Thrombocytopenic Purpura (TTP)
Renal platelet thrombi	Shiga toxin Factor H plasmatic deficiency	Hemolytic Uremic Syndrome (HUS) associated to <i>E. Coli</i> infection (children) Familial/recurrent HUS
Systemic and renal thrombi	Transplant Drugs (mitomicin, cyclosporin)	HUS o TTP

TTP pathogenesis




HUS pathogenesis (I)


HUS pathogenesis (II)



Renal thrombotic microangiopathy with vessels occlusion



Anti-fibrinogen serum





Clinical presentation

- Thrombocytopenia with increased megakaryocytes
- Red blood cell fragmentation
- Lactate dehydrogenase (LDH) increase

Clinic pentad

- Thrombocytopenia
- Microangiopathic hemolytic anemia
- Neurological disorders
- Renal failure
- Fever


Schistocyte genesis





Schistocytes




- Red blood cells fragments of triangular/crescent/ helmet form with rectilinear profile segment testifying the zone of break
- Observed on blood smears
- They result from mechanical, toxic or heat-induced damage of normal RBC
- They appear under several conditions (after surgery, solid organ and/or bone marrow transplantation, HIV infection, in diseases with cardiac and vessel abnormalities, pre-eclampsia, severe renal diseases, gastric carcinoma)
- Often the earliest sign of thrombotic microangiopathy (TMA): detection and quantification are thus of primary importance
- Morphological identification requires well-trained hematologists/biologists









Diseases & Schistocytes

- Mechanical hemolytic anemias
- Microangiopathic hemolytic anemias
 - Disseminated Intravascular Coagulation (DIC)
 - Hemolytic Uremic Syndrome (HUS)
 - Thrombotic Thrombocytopenic Purpura (TTP)
- Other anemias
- Surgery
- Transplant Associated Microangiopathy (TAM)
- Vessels inflammatory diseases
- Vessels abnormalities
- Infectious diseases
- Bone marrow pathologies (primary and secondary)

Classical Reference values

Adults: $\leq 0.1\%$

Newborn: 0.3-1.9%

Preterms: $\leq 5.5\%$

► Schistocytes are usually

- specifically requested by clinicians
- counted on PB smears by optical microscope
- expressed as % of 500-1000 red blood cells

Table 7-3. Confidence Limits (95%) for Various Percentages of Blood Cells of a Given Type as Determined by Differential Counts

<i>a</i>	<i>n</i> = 100	<i>n</i> = 200	<i>n</i> = 500	<i>n</i> = 1,000	<i>n</i> = 10,000
0	0 - 3.6	0 - 1.8	0 - 0.7	0 - 0.4	0 - 0.1
1	0.0- 5.4	0.1- 3.6	0.3- 2.3	0.5- 1.8	0.8- 1.3
2	0.2- 7.0	0.6- 5.0	1.0- 3.6	1.2- 3.1	1.7- 2.3
3	0.6- 8.5	1.1- 6.4	1.7- 4.9	2.0- 4.3	2.6- 3.4
4	1.1- 9.9	1.7- 7.7	2.5- 6.1	2.9- 5.4	3.6- 4.5
5	1.6- 11.3	2.4- 9.0	3.3- 7.3	3.7- 6.5	4.5- 5.5
6	2.2- 12.6	3.1- 10.2	4.1- 8.5	4.6- 7.7	5.5- 6.5
7	2.9- 13.9	3.9- 11.5	4.9- 9.6	5.5- 8.8	6.5- 7.6
8	3.5- 15.2	4.6- 12.7	5.8- 10.7	6.4- 9.9	7.4- 8.6
9	4.2- 16.4	5.4- 13.9	6.6- 11.9	7.3- 10.9	8.4- 9.6
10	4.9- 17.6	6.2- 15.0	7.5- 13.0	8.2- 12.0	9.4- 10.7
15	8.6- 23.5	10.4- 20.7	12.0- 18.4	12.8- 17.4	14.3- 15.8
20	12.7- 29.2	14.7- 26.2	16.6- 23.8	17.6- 22.6	19.2- 20.8
25	16.9- 34.7	19.2- 31.6	21.3- 29.0	22.3- 27.8	24.1- 25.9
30	21.2- 40.0	23.7- 36.9	26.0- 34.2	27.2- 32.9	29.1- 31.0
35	25.7- 45.2	28.4- 42.0	30.8- 39.4	32.0- 38.0	34.0- 36.0
40	30.3- 50.3	33.2- 47.1	35.7- 44.4	36.9- 43.1	39.0- 41.0
45	35.0- 55.3	38.0- 52.2	40.6- 49.5	41.9- 48.1	44.0- 46.0
50	39.8- 60.2	42.9- 57.1	45.5- 54.5	46.9- 53.1	49.0- 51.0
55	44.7- 65.0	47.8- 62.0	50.5- 59.4	51.9- 58.1	54.0- 56.0
60	49.7- 69.7	52.9- 66.8	55.6- 64.3	56.9- 63.1	59.0- 61.0
65	54.8- 74.3	58.0- 71.6	60.6- 69.2	62.0- 68.0	64.0- 66.0
70	60.0- 78.8	63.1- 76.3	65.8- 74.0	67.1- 72.8	69.0- 70.9
75	65.3- 83.1	68.4- 80.8	71.0- 78.7	72.2- 77.7	74.1- 75.9
80	70.8- 87.3	73.8- 85.3	76.2- 83.4	77.4- 82.4	79.2- 80.8
85	76.5- 91.4	79.3- 89.6	81.6- 88.0	82.6- 87.2	84.2- 85.7
90	82.4- 95.1	85.0- 93.8	87.0- 92.5	88.0- 91.8	89.3- 90.6
91	83.6- 95.8	86.1- 94.6	88.1- 93.4	89.1- 92.7	90.4- 91.6
92	84.8- 96.5	87.3- 95.4	89.3- 94.2	90.1- 93.6	91.4- 92.6
93	86.1- 97.1	88.5- 96.1	90.4- 95.1	91.2- 94.5	92.4- 93.5
94	87.4- 97.8	89.8- 96.9	91.5- 95.9	92.3- 95.4	93.5- 94.5
95	88.7- 98.4	91.0- 97.6	92.7- 96.7	93.5- 96.3	94.5- 95.5
96	90.1- 98.9	92.3- 98.3	93.9- 97.5	94.6- 97.1	95.5- 96.4
97	91.5- 99.4	93.6- 98.9	95.1- 98.3	95.7- 98.0	96.6- 97.4
98	93.0- 99.8	95.0- 99.4	96.4- 99.0	96.9- 98.8	97.7- 98.3
99	94.6- 99.9	96.4- 99.9	97.7- 99.7	98.2- 99.5	98.7- 99.2
100	96.4-100	98.2-100	99.3-100	99.6-100	99.9-100



Adults: $\leq 0.1\%$

Newborns: 0.3-1.9%


Preterms: $\leq 5.5\%$

Automated red cell fragments

Automated Red Cell Fragment Abbott Sapphire Coulter DXH800



Schistocytes analysis



CD235a antibody applied in the CD-Sapphire automated Immunoplatelet assay, allows the qualitative demonstration of RBC schistocytes and RBC microparticles


Scott et al. personal communication 2007

Abbott Patent
Date: 5/8 May 2008

33

Abbott
Diagnostics

Schistocytes analysis



CD61 antibody in the CD-Sapphire automated Immunoplatelet assay can easily be substituted with CD235a, for demonstrating glycophorin-A on membranes of red blood cells and RBC fragments

Abbott Patent
Date: 5/8 May 2008

34

Abbott
Diagnostics



RBC fragments flag & quantitation: Sysmex XE-2100 method

➤ Flag for presence of fragments is automatically provided by the XE-2100 analyser.

➤ The count is performed by gating an area on the Retics channel scattergram where whole blood is stained with a fluorescent dye.

➤ The forward scatter and the intensity of fluorescence allow identification and count of RBC fragments.

➤ They correspond to events with a volume smaller than RBC and with RNA content lower than platelets.




FRC#	0.0106	10 ⁶ /uL
FRC%	0.33	%

RBC fragments identification and enumeration with the ADVIA 2120 method

► integrated analysis of RBC and platelet count

► events with a volume smaller than 30 fL and with a refractive index greater than 1.4

► frequency of events above the threshold of 10,000/ μ L



RBC Fragments	0,02	$\times 10^6$ cells/ μ L
RBC Ghosts	0,01	$\times 10^6$ cells/ μ L

Automated FRC compared with visual count

Automated screening for schistocytes with two hematology analyzers.

All the 150 samples were smeared and stained with MGG panoptical stain and evaluated by two expert observers at microscope independently.

We found a fully concordance between the reference method and the automated enumeration with both the analyzers without any false negative (**Fig. 5 and 6**).

The range values of positive samples were as follow:

reference method :0,1-2,3%.

ADVIA 2120 method: 0,2-4,13%

XE-2100 method: 0,05-8,39 %

The overall correlation of the analyzers' count versus the reference method was as follows:



$y = 2,0943x + 0,4242$, $R^2 = 0,3098$ for the XE-2100 method (**Fig. 7**)


$y = 1,0103x + 0,3109$, $R^2 = 0,4657$ for the ADVIA 2120 method (**Fig. 9**).


Both analyzers showed a trend toward an overestimation of RBC fragment count, apparently due to the inclusion into the count of microspherocytes, when present (**Fig. 8**).

Authors: 2005, ISLH


M. Garzia, A. Di Mario,
E. Rossi, G. Massini, S. Bellesi,
G. d'Onofrio, G. Zini







Follow- up



Param.	Dati	Unit	Unit'
RBC	2.25	-	10 ⁶ /uL
RBC-O	2.13	-	10 ⁶ /uL
HGB	6.3	-	g/dL
HCT	20.2	-	%
MCV	89.8	-	fL
MCH	28.0	-	pg
MCHC	31.2	-	g/dL
RDW-SD	113.8	+	fL
RDW-CV	35.0	+	%
PLT &	51	*	10 ³ /uL
PLT-I	46	*	10 ³ /uL
PLT-O	51	*	10 ³ /uL
PDW	----	-	fL
MPV	----	-	fL
P-LCR	----	-	%
PCT	----	-	%
RET#	0.5036	*	10 ⁶ /uL
RET%	22.38	*	%
IRF	10.4	*	%
LFR	89.6	*	%
MFR	7.1	*	%
HFR	3.3	*	%


Param.	Dati	Unit	Unit'
RET-He	36.9	*	pg
RBC-He	25.4	*	pg
D-He	11.5	*	pg
RET-Y	188.1	*	ch
RBC-Y	150.1	*	ch
IRF-Y	191.3	*	ch

Param.	Dati	Unit	Unit'
FRC#	0.2466	-	10 ⁶ /uL
FRC%	10.96	-	%

Param.	Dati	Unit	Unit'
NRBC#	0.08	-	10 ³ /uL
NRBC%	0.9	-	/100WBC

Flag(s)

RBC/RET	PLT
Fragments?	PLT Abn Dst
RET Abn Scg	Thrombo-
Reticulo	
Aniso	



Param.	Dati	Unit	Unit'
WBC &	8.84	-	10 ³ /uL
NRBC+W	8.92	-	10 ³ /uL

Param.	Dati	Unit	Unit'
NRBC#	0.08	-	10 ³ /uL
NRBC%	0.9	-	/100WBC

Param.	Dati	Unit	Unit'
Area#	0.006	-	10 ³ /uL
Area%	0.07	-	%

Flag(s)


Mono+
IG Present




Extended Differential

Param.	Dati	Unit	Unit'
IG#	0.37	-	10 ³ /uL
NEUT#&	5.07	-	10 ³ /uL
LYMP#&	1.69	-	10 ³ /uL
MONO#	1.65	+	10 ³ /uL
EO#	0.04	-	10 ³ /uL
BASO#	0.02	-	10 ³ /uL
OTHER#	0.00	-	10 ³ /uL

Param.	Dati	Unit	Unit'
IG%	4.2	-	%
NEUT%&	57.3	-	%
LYMP%&	19.1	-	%
MONO%	18.7	+	%
EO%	0.5	-	%
BASO%	0.2	-	%
OTHER%	0.0	-	%




Param.	Dati	Unit	Unit'
IPF	12.4	-	%
H-IPF	5.1	-	%
IPF#	6.3	-	10 ³ /uL
PLT-X	24.8	-	ch





Emocromo di routine			
WBC	9.11	x10 ³ /μL	
RBC L	2.28	* x10 ⁶ /μL	
HGB L	6.8	* g/dL	
HCT L	22.0	* %	
MCV	96.6	* fL	
MCH	29.7	* pg	
MCHC L	30.8	* g/dL	
CHCM L	33.0	* g/dL	
CH	31.3	* pg	
RDW	31.3	* %	
HDW	5.08	* g/dL	
PLT	51	x10 ³ /μL	
MPV	7.5	fL	

%Blasti	2.7	
%lper	5.7	
%lpo	14.9	
%Macro	21.0	
%Micro	10.7	
Frammenti RBC	0.09	x10 ⁶ /μL
Ombre RBC	0.04	x10 ⁶ /μL
Neut X	61.2	
Neut Y	65.8	
MNx	12.2	
MNy	13.2	
%MN	38.0	
%PMN	60.8	
HGB Calc	7.3	g/dL



$$0,09 \times 100 / 2.28 = 3,94\%$$

Formula WBC di routine			
WBC	%	#	
Neutro	63.6	5.80	x10 ³ /μL
Linfo	L 18.6	1.70	x10 ³ /μL
Mono	H 13.0	H 1.19	x10 ³ /μL
Eos	1.4	0.12	x10 ³ /μL
Baso	0.3	0.03	x10 ³ /μL
LUC	3.1	0.28	x10 ³ /μL
NRBC			x10 ³ /L
Indice Lobularità		2.09	
MPXI		-4.8	
WBCP		8.28	x10 ³ /μL

Retic			
RBC neg	63.61	#	
Retic H	36.39	* H	830.5
Retic L	59.24		4742
Retic M	29.23		2340
Retic H	11.53		923
IRF-H	11.53		
IRF-M+H	40.76		
Acquired Cells Retic			25231
Analyzed Cells Retic			22293
Gated Cells Retic			21998
Retic Count			8005

Allarmi morfolog...	
Micro	+++
Macro	+++
IPOCROMIA	+++
IPERCROMIA	+
ANISO	+++
HC VAR	+++

Retic di routine			
Retic	H 36.39	* H	830.5
CHr		H	34.9
CHm			27.5

Fragmented red blood cells automated measurement is a useful parameter to exclude schistocytes on the blood film

J.-F. LESESVE*, V. ASNAFI†, F. BRAUN‡, G. ZINI§,¶

Table 1. Reference range for fragmented red cells (FRC)

Reference	Center	Analyzer	No. of tests	Population	Fragmented red cells (%)				
					Mean	Min-max	SD	95% CI	Median
Lesesve 2004	Nancy, Fr	ADVIA 120	69	Adults		<0.25			
Lesesve 2007	Nancy, Fr	ADVIA 120	120	Adults	0.258	0.18–0.49	0.089	0.213–0.257	0.22
This study	Nancy, Fr	ADVIA 2120	1 984	Adults	0.247	0.15–0.48	0.08		0.23
This study	Roma, It	ADVIA 2120	80	Adults	0.30	0.17–0.48	0.13		0.34
This study	Roma, It	ADVIA 2120	10	Preterm newborns	0.80	0.19–1.24			
Jiang 2001	Kobe, Jpn	XE-2100	762	Adults		0.03–0.56			
Abe 2009	Mie, Jpn	XE-2100	120	Adults				0–0.205	0.04
This study	Roma, It	XE-2100	146	Adults	0.69	0.2–2.83	0.74		0.33
This study	Paris, Fr	XE-2100	1405	Adults		<0.50			
This study	Nancy, Fr	XE-2100	232	Adults	0.36	0.05–0.65	0.125	0.31–0.37	0.34
This study	Thionville, Fr	XE-5000	111	Adults	0.33	0–2.96	0.148		1.1
This study	Roma, It	XE-2100	17	Preterm newborns	3.44	0.12–11.65			

Results: Reference range for FRC was <0.3% for the ADVIA and <0.5% for the XE-2100. The presence of FRC below a threshold determined at 1% (ADVIA and XE-2100) had a negative PV close to 100% to exclude the presence of schistocyte on the blood smear, but in relationship with a poor PV value.

Table 3. Sensitivity, specificity, and predictive value of FRC

Counter	Question assessed	Number and type of patients	Center	FRC %	Sensitivity	Specificity	Positive predictive value	Negative predictive value
ADVIA 2120	Occurrence of TAM	69, post BMT	Nancy	0.25	1	0.734	0.227	1
				1	0.80	0.953	0.571	0.984
	Presence of schistocyte on the blood smear/TAM	131, unselected	Nancy	0.25	1	0.171	0.23	1
				1	0.885	0.876	0.639	0.968
	Presence of schistocyte on the blood smear	100, unselected	Roma	0.2	0.918	0.576		
XE-2100	Presence of schistocyte on the blood smear	300, unselected	Paris	0.5	0.925	0.457	0.268	0.966
	Presence of schistocyte on the blood smear	574, suspicion of TAM	Paris	0.5	0.952			0.987
	Presence of schistocyte on the blood smear	831, unselected	Paris	0.5	0.967			0.993
	Presence of schistocyte on the blood smear	100, unselected	Roma	0.2	0.959	0.695		
	Occurrence of TAM	230	Mie, Jpn	1.2	0.9	0.96	0.9	0.9




ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes

G. ZINI*, G. D'ONOFRIO[†], C. BRIGGS[‡], W. ERBER[§], J. M. JOU[¶], S. H. LEE^{**}, S. MCFADDEN^{††},
J. L. VIVES-CORRONS[¶], N. YUTAKA^{‡‡}, J. F. LESEVE^{§§}

Consensus on morphological description/identification (I)

Bitten erythrocyte:

Normal size, shape irregular with a defective amputated zone



Schistocyte (keratocyte):

Helmet shape: decreased size (surface/area), irregular shape with a defective amputated zone highlighted by a rectilinear border ending with usually 2 (1 or 3 possible) angulated spicules. Pale central zone is not observed.



Schistocyte


Triangular shape: reduced size, irregular shape with a defective amputated zone highlighted by a rectilinear sometime spiculated border, ending with 2 angulated spicules. Pale central zone is not observed.



Consensus on morphological description/identification (II)



Fragment

Small/very small size, highly irregular shape




Microspherocytes

Small size, round shape, hyperdensity (increased staining)



Irregularly contracted cells

Small size, hyperdensity, irregular outline sometimes with small protrusions and Heinz bodies





ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes

G. ZINI*, G. D'ONOFRIO[‡], C. BRIGGS[‡], W. ERBER[§], J. M. JOU[†], S. H. LEE^{**}, S. MCFADDEN^{**}, J. L. VIVES-CORRONS[†], N. YUTAKA^{**}, J. F. LESESVE^{§§}

Table 1. International Council for Standardization in Haematology recommendations for schistocyte counting

1. Schistocytes should be evaluated on peripheral blood smears using an optical microscope at medium magnification and estimated as a percentage after counting at least 1000 red blood cells
2. A schistocyte count should be requested and carried out when a diagnosis of thrombotic microangiopathies caused by red cell mechanical damage is suspected, usually in patients with thrombocytopenia
3. Schistocytes should be identified by specific positive morphological criteria. Schistocytes are always smaller than intact red cells and can have the shape of fragments with sharp angles and straight borders, small crescents, helmet cells, keratocytes, or microspherocytes*
4. A schistocyte count should be considered clinically meaningful if schistocytes represent the main morphological red blood cells abnormality in the smear (other than signs of erythropoietic regeneration)
5. A robust morphological indication for the diagnosis of thrombotic microangiopathic anemia in adults should be recognized when the percentage of schistocytes is above 1%
6. Fragmented red cell enumeration by automated blood cell counters should be considered a useful complement to microscopic evaluation, as it provides rapid results with a high predictive value of negative samples. A microscope check is needed for positive and macrocytic samples†

*Microspherocytes only in the presence of other mentioned RBC shapes.

†Macrocytic samples are at risk of underestimation or absence of flag ('false-negative' test).




Figure 1. Typical shapes for specific identification of schistocytes. (a) keratocyte (upper arrow) and helmet cell (lower arrow), close to a polychromatophilic erythrocyte in the left lower corner; (b) a triangle schistocyte (arrow) with a helmet cell on the upper right; (c) two microspherocytes (arrows); they are derived, in a context of thrombotic microangiopathic anemia, from schistocytes.

Figure 2. Peripheral blood smear from a case of thrombotic thrombocytopenic purpura. (a) arrows indicate a helmet cells (lower left), a microspherocyte (upper left), a keratocyte (center top), and a microcrescent (lower right angle); (b) morphological abnormalities include microspherocytes, keratocytes, helmet cell, and several crescent and triangular schistocytes.







Figure 3. Peripheral blood smear from a case of post-transplant thrombotic microangiopathic anemia. (a) a keratocyte (left arrow), a helmet cell (right arrow), and several hyperchromatic triangular erythrocytes are present; (b) two keratocytes (upper arrow) and two deformed microspherocytes (lower arrow) are present, together with more bizarre red cell fragments.




Flow chart



Normal



Helmet Cells



Normal




Keratocytes



Normal



Schistocytes (Schizocytes)



Therapeutic dilemma in the management of a patient with the clinical picture of TTP and severe B12 deficiency.

Walter K¹, Vaughn J², Martin D³.

Table 1

Characteristics of pseudo-TTP patients individually reported in the literature and averages from a case series

Case	Year	Sex	Age	WBC (×10 ⁹ /L)	HCT	HGB	PLT (nadir) (×10 ⁹ /L)	LDH (IU/L)	MCV (fL)	Retic × 10 ⁹ /L	TPE	Ref
1	1998	F	38	3.6		39	260	5700	102	20	NO	[22]
2	1999	F	68	3.2		32	110	7900	112	34	YES	[23]
3	2003	M	38	2.2		45	50	19,384	90	10	YES	[24]
4	2008	M	48	6.3		50	380	8988	80	13	YES	[14]
5	2009	M	52	3.6	27		960	4604	107	31	NO	[25]
6	2011	F	31	4.2		57	420	4579	110	NR	YES	[26]
Mean values from seven patients												
Series			72	3.4		42	73	7310	111	13		[10]

Morphological changes of red blood cells in peripheral blood smear of patients with pregnancy-related hypertensive disorders.

Hernández Hernández JD¹, Villaseñor OR¹, Del Rio Alvarado J¹, Lucach RO¹, Zárate A², Saucedo R², Hernández-Valencia M³.

RESULTS: A total of 119 samples were analyzed; 74% showed abnormal morphology of erythrocytes and the most frequent abnormality was the presence of schistocytes in up to 39% of samples. Descriptive analysis showed a degree of association to independent variables with Cramer's V = 0.41 value (p <0.05).

CONCLUSIONS: A high percentage of patients with hypertensive disorders of pregnancy show some morphologic alterations of erythrocytes in peripheral blood smear.

Evaluation of schistocyte analysis by a novel automated digital cell morphology application.

Hervent AS¹, Godefroid M¹, Cauwelier B¹, Billiet J¹, Emmerechts J¹.

RESULTS: Within-run, between-run and between-observer coefficients of variation were lower when counted with the CellaVision compared to the manual microscopic count. The very high sensitivity but rather poor specificity implicates the need for reclassification by the operator, following automated analysis. After reclassification, method comparison studies revealed good agreement with the manual microscopic method, with however slightly higher values of schistocytes for the automated analysis.

CONCLUSION: The CellaVision Advanced RBC Software Application provides a sensitive and reproducible measurement of schistocytes in peripheral blood, but still requires manual revision. Furthermore, it is an easy-to-use software and an excellent teaching tool that might contribute to standardization in the investigation of schistocyte-related conditions.

